Papers/PMID:38987824
Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial.
Journal of ovarian research2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
resveratrol — no detected effect on clinical pregnancy rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Furthermore, there were no significant differences detected between the resveratrol and placebo groups in terms of chemical pregnancy or clinical pregnancy rates (45.83% (11/24) vs. 33.33% (8/24); two-tailed P = 0.5556; 37.50% (9/24) vs. 29.17% (7/24); two-tailed P = 0.7601; Fig. 5).”
Quoted verbatim from Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 2 months
- Dose
- 800 mg/day (2 x 400 mg capsules) trans-resveratrol for 60 days before oocyte collection
- Population
- Women aged 18-35 with polycystic ovary syndrome undergoing ICSI; transfer cycles after oocyte retrieval
Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial.2024PMID:38987824Permalink